What Did People with Chronic Neuropathy Pain Say?
Since the launch of the Quell chronic pain management device this past summer, our team has been eager to learn about users’ real-world experience to treat the pain and discomfort associated with diabetic neuropathy. Thanks to help from the diabetes market research company dQ&A, we invited five volunteers with diabetic neuropathy or other forms of chronic pain to use the no-prescription-required (“over-the-counter”), FDA-cleared Quell device and app for two weeks. Read below for more information on Quell and what these five people had to say about it!
Quell offers a potentially life-changing experience for people suffering from chronic pain. While the cost may be high for some ($249 upfront + $30 per month), we see it as a low-risk (there’s a money-back guarantee), high-reward opportunity to significantly improve quality of life for people living with often debilitating diabetic neuropathy. For sure, there will be some who experience no pain relief from Quell (~20% of people, according to NeuroMetrix), and others more who will find the burden of wearing the calf-worn device to outweigh the pain relief it provides. Still, chronic pain remains a major unmet need in diabetes, and many people have experienced very limited success from pain medications alone. We applaud NeuroMetrix for an innovative, effective, FDA-cleared product that clearly incorporated a lot of thinking on the patient experience.
Plus – fresh out of the Consumer Electronics Show – it was just announced that a second-generation version of Quell has received FDA clearance. This updated version contains advancements in tracking capabilities, an extended battery life of up to 25%, and more. It will be available in March of 2016 – more details below!
We're here for you.or call 800.204.6577